Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer

Antonin Levy¹, Cécile Le Péchoux², Corinne Faivre-Finn³

Affiliations

¹ Department of Radiation Oncology, Institut d'Oncologie Thoracique, Gustave Roussy, Villejuif, France; Univ Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France; INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
² Department of Radiation Oncology, Institut d'Oncologie Thoracique, Gustave Roussy, Villejuif, France.
³ Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, UK; Department of Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester M20 4BX, UK. Electronic address: corinne.finn@nhs.net.

PMID: 34087130
DOI: 10.1016/S1470-2045(21)00255-2

Comment

Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer

Antonin Levy et al. Lancet Oncol. 2021 Jun.

. 2021 Jun;22(6):e220.

doi: 10.1016/S1470-2045(21)00255-2.

Authors

Antonin Levy¹, Cécile Le Péchoux², Corinne Faivre-Finn³

Affiliations

¹ Department of Radiation Oncology, Institut d'Oncologie Thoracique, Gustave Roussy, Villejuif, France; Univ Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France; INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
² Department of Radiation Oncology, Institut d'Oncologie Thoracique, Gustave Roussy, Villejuif, France.
³ Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, UK; Department of Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester M20 4BX, UK. Electronic address: corinne.finn@nhs.net.

PMID: 34087130
DOI: 10.1016/S1470-2045(21)00255-2

No abstract available

PubMed Disclaimer

Conflict of interest statement

CLP reports honoraria from AstraZeneca, Amgen, Nanobiotix, Roche, Medscape, and Lilly; and personal fees from PrimeOncology, outside the submitted work. All other authors declare no competing interests.

Comment in

Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer - Authors' reply.
Grønberg BH, Langer SW, Nyman J, Halvorsen TO. Grønberg BH, et al. Lancet Oncol. 2021 Jun;22(6):e222. doi: 10.1016/S1470-2045(21)00291-6. Lancet Oncol. 2021. PMID: 34087132 No abstract available.

Comment on

High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial.
Grønberg BH, Killingberg KT, Fløtten Ø, Brustugun OT, Hornslien K, Madebo T, Langer SW, Schytte T, Nyman J, Risum S, Tsakonas G, Engleson J, Halvorsen TO. Grønberg BH, et al. Lancet Oncol. 2021 Mar;22(3):321-331. doi: 10.1016/S1470-2045(20)30742-7. Lancet Oncol. 2021. PMID: 33662285 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer

Affiliations

Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical